Several polymorphisms in genes that encode platelet components (receptors or enzymes),
or cytochrome P450 enzyme isoforms, involved in clopidogrel metabolism, have been …

The loss-of-function hepatic cytochrome P450 (CYP) 2C19* 2 allele has been associated
with reduced clopidogrel active metabolite generation and higher ex vivo platelet reactivity …

Background Pharmacogenetic determinants of the response of patients to clopidogrel
contribute to variability in the biologic antiplatelet activity of the drug. The effect of these …

Background Clopidogrel and low-dose aspirin have become the mainstay oral antiplatelet
regimen to prevent recurrent ischaemic events after acute coronary syndromes or stent …

Summary Background Cytochrome P450 2C19 (CYP2C19) is the principal enzyme
responsible for converting clopidogrel into its active metabolite, and common genetic …

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and
pharmacodynamcis of clopidogrel. Twenty‐four subjects were divided into three groups on …

Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …

Aims To perform a meta-analysis of the association between CYP2C19 loss-and gain-of-
function variants and cardiovascular outcomes and bleeding in patients with coronary artery …

Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

Aims Clinical trials have established the value of clopidogrel therapy in a wide spectrum of
patients with cardiovascular diseases. Both loss-and gain-of-function single nucleotide …